RxDoctor Payments Data

James Hunt, MD

Critical Care Medicine · Greenwood Village, CONPI 1437205069

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (44.5%), education and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Intuitive Surgical at 56.4% of the total. Reporting peaked in 2023 at $5,736 and has fallen 89.4% since, to $608 in 2025.

$9,158in general payments, 2019–2025

Across 98 payments — averaging $93.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Inari Medical, Inc.$878
  • Actelion Pharmaceuticals US, Inc.$581
  • AstraZeneca$316
  • Bayer$273
  • GSK$185
  • plus $2K from 18 others

What the payments were for

  • Consulting fees$2002%
  • Travel & lodging$1,86720%
  • Food & beverage$4,07144%
  • Education$3,02033%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,158 in reported general payments places this provider in the 85th percentile of 141 critical care medicine providers in Colorado.

See all critical care medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$92,177
Medicare patients
285
Services billed
787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat20$278,925
Pirfenidone21$62,799
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$53,611
Ambrisentan24$49,140
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$28,748
Incruse ElliptaUmeclidinium Bromide37$17,934
Breo ElliptaFluticasone/Vilanterol13$11,706
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$9,583
SymbicortBudesonide/Formoterol Fumarate16$8,871
Mycophenolate Mofetil23$3,877
Sildenafil Citrate19$1,234
Albuterol Sulfate HfaAlbuterol Sulfate20$652
Prednisone22$104
Furosemide32$80
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$273$278,92520 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$185$83,251105 claims
AstraZenecaBreztri Aerosphere, Symbicort$316$37,61839 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 141 critical care medicine providers in Colorado.

Other critical care medicine in Greenwood Village

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →